Oral GLP-1s Beyond the Hype: The Polypharmacy Challenge

This article explores the rising promise of oral GLP-1 therapies and the growing complexity they introduce in modern care. While these treatments are generating excitement for their effectiveness in obesity and metabolic disease, experts highlight a critical challenge: managing polypharmacy and ensuring patient safety as options expand.

Dr. Evan Nadler brings a grounded clinical perspective, emphasizing the importance of thoughtful integration of these therapies into real-world treatment plans—balancing innovation with practicality, patient adherence, and long-term outcomes. His insights reinforce that while the science is advancing rapidly, success ultimately depends on how well these therapies are applied in everyday care.

Read the full article here.